Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Front-of-package nutrition labeling and obesity implications.

American journal of preventive medicine·2011

Same author

Random plasma glucose measurement may improve the diagnostic specificity of highly sensitive troponin in the emergency department.

International journal of cardiology·2011

Same author

Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I.

Clinical chemistry and laboratory medicine·2011

Same author

Intermittent hypobaric hypoxia applicability in myocardial infarction prevention and recovery.

Journal of cellular and molecular medicine·2011

Same author

Fibrinogen replacement therapy: a critical review of the literature.

Blood transfusion = Trasfusione del sangue·2011

Same author

Cardiac troponins and physical exercise. It's time to make a point.

Biochemia medica·2011

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Acquired factor V inhibitors: a systematic review.

Massimo Franchini¹, Giuseppe Lippi

¹Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. mfranchini@ao.pr.it

Journal of Thrombosis and Thrombolysis

|November 6, 2010

Summary

Factor V (FV) inhibitors are rare but serious, causing bleeding risks. This review focuses on non-bovine thrombin causes, excluding outdated surgical treatments.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Jun 7, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Area of Science:

Hematology
Coagulation Disorders
Immunology

Background:

Acquired inhibitors against coagulation factor V (FV) are uncommon and complex.
Historically linked to topical bovine thrombin during surgery, this cause is now obsolete.
FV inhibitors present a spectrum from asymptomatic findings to severe hemorrhage.

Purpose of the Study:

To systematically review non-bovine thrombin-related cases of acquired factor V inhibitors.
To understand the current landscape of FV inhibitor development.
To identify potential triggers and clinical implications beyond historical associations.

Main Methods:

Systematic literature review.
Focused on cases not associated with bovine thrombin exposure.
Analysis of reported clinical presentations and outcomes.

Main Results:

FV inhibitors can manifest with varying severity, from mild lab anomalies to life-threatening bleeds.
The review identifies and analyzes cases independent of the previously common bovine thrombin trigger.
Clinical data on non-bovine thrombin-related inhibitors provides insights into current etiological factors.

Conclusions:

Non-bovine thrombin-related FV inhibitors represent a significant clinical challenge.
Understanding these cases is crucial for accurate diagnosis and management.
Further research into novel triggers and therapeutic strategies is warranted.